These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17046987)

  • 1. Improving patient outcomes in schizophrenia: achieving remission.
    Nasrallah HA; Lasser R
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concepts of remission and recovery in schizophrenia.
    Leucht S; Lasser R
    Pharmacopsychiatry; 2006 Sep; 39(5):161-70. PubMed ID: 16944406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience and management considerations with long-acting risperidone.
    Parellada E
    Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
    Nasrallah HA; Dursun SM
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):3-5. PubMed ID: 17046983
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs and the quality of life: the patient's point of view.
    Diamond R
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):29-35. PubMed ID: 2859278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission in schizophrenia: applying recent consensus criteria to refine the concept.
    Lasser RA; Nasrallah H; Helldin L; Peuskens J; Kane J; Docherty J; Tronco AT
    Schizophr Res; 2007 Nov; 96(1-3):223-31. PubMed ID: 17765480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychopharmacotherapy and remission of patients with schizophrenia.
    Degmecić D; Pozgain I; Filaković P; Dodig-Curković K; Mihanović M
    Coll Antropol; 2009 Jun; 33(2):547-51. PubMed ID: 19662777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.